January | 2014 | Peptonic Medical

Home / 2014 / January

PEPTONIC medical raises SEK 6.9 million

- January 23, 2014

PEPTONIC medical today announced that it has raised SEK 6.9 million in a directed private placement to existing and new shareholders. After the private placement, the number of shareholders in

About us

PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.

PEPTONIC medical raises SEK 6.9 million

Recent Posts

Recent Comments

Archives

Categories

Meta

All press releases on Spotlightstockmarket.com

About us

Contact us

Dataskyddspolicy

Navigation